These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 27510251)

  • 81. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
    Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
    Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Pharmacokinetics of rifampicin in Mexican patients with tuberculosis and healthy volunteers.
    Medellín-Garibay SE; Milán-Segovia Rdel C; Magaña-Aquino M; Portales-Pérez DP; Romano-Moreno S
    J Pharm Pharmacol; 2014 Oct; 66(10):1421-8. PubMed ID: 24841364
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
    Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR
    Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes.
    McIlleron H; Hundt H; Smythe W; Bekker A; Winckler J; van der Laan L; Smith P; Zar HJ; Hesseling AC; Maartens G; Wiesner L; van Rie A
    Int J Tuberc Lung Dis; 2016 Jul; 20(7):915-9. PubMed ID: 27287644
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants.
    Ho RH; Choi L; Lee W; Mayo G; Schwarz UI; Tirona RG; Bailey DG; Stein CM; Kim RB
    Pharmacogenet Genomics; 2007 Aug; 17(8):647-56. PubMed ID: 17622941
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Rifampicin serum levels in childhood tuberculosis.
    Thee S; Detjen A; Wahn U; Magdorf K
    Int J Tuberc Lung Dis; 2009 Sep; 13(9):1106-11. PubMed ID: 19723399
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Simultaneous determination of efavirenz, rifampicin and its metabolite desacetyl rifampicin levels in human plasma.
    Fox D; O'Connor R; Mallon P; McMahon G
    J Pharm Biomed Anal; 2011 Dec; 56(4):785-91. PubMed ID: 21840662
    [TBL] [Abstract][Full Text] [Related]  

  • 88. SLCO1B1 rs4149056 genetic polymorphism predicting methotrexate toxicity in Chinese patients with non-Hodgkin lymphoma.
    Yang L; Wu H; Gelder TV; Matic M; Ruan JS; Han Y; Xie RX
    Pharmacogenomics; 2017 Nov; 18(17):1557-1562. PubMed ID: 29095107
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
    Birmingham BK; Bujac SR; Elsby R; Azumaya CT; Wei C; Chen Y; Mosqueda-Garcia R; Ambrose HJ
    Eur J Clin Pharmacol; 2015 Mar; 71(3):341-55. PubMed ID: 25673568
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure.
    Endo S; Fukahori A; Tokuhiro S; Shinagawa A; Walker J; Yoshihara K; Ishizuka H; Ieiri I; Sugiyama Y
    J Hum Genet; 2012 Aug; 57(8):531-44. PubMed ID: 22695893
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and Simulation.
    Barnett S; Ogungbenro K; Ménochet K; Shen H; Lai Y; Humphreys WG; Galetin A
    Clin Pharmacol Ther; 2018 Sep; 104(3):564-574. PubMed ID: 29243231
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin.
    Zhang D; Ding Y; Wang X; Xin W; Du W; Chen W; Zhang X; Li P
    Eur J Clin Pharmacol; 2020 Jul; 76(7):939-946. PubMed ID: 32361904
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Influence of ABCB-1 C3435T polymorphisms on plasma nevirapine and efavirenz levels and their effects on virologic and immunological outcomes in HIV/TB co-infected Thai adults under anti-retroviral therapy.
    Uttayamakul S; Likanonsakul S; Manosuthi W; Wichukchinda N; Shioda T; Khusmith S
    Southeast Asian J Trop Med Public Health; 2012 Jan; 43(1):78-88. PubMed ID: 23082557
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Development of population pharmacokinetics model and Bayesian estimation of rifampicin exposure in Indonesian patients with tuberculosis.
    Soedarsono S; Jayanti RP; Mertaniasih NM; Kusmiati T; Permatasari A; Indrawanto DW; Charisma AN; Lius EE; Yuliwulandari R; Quang Hoa P; Ky Phat N; Thu VTA; Ky Anh N; Ahn S; Phuoc Long N; Cho YS; Shin JG
    Tuberculosis (Edinb); 2023 Mar; 139():102325. PubMed ID: 36841141
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers.
    Padgaonkar KA; Revankar SN; Bhatt AD; Vaz JA; Desai ND; D'Sa S; Shah V; Gandewar K
    Int J Tuberc Lung Dis; 1999 Jul; 3(7):627-31. PubMed ID: 10423226
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Triglyceride associated polymorphisms of the APOA5 gene have very different allele frequencies in Pune, India compared to Europeans.
    Chandak GR; Ward KJ; Yajnik CS; Pandit AN; Bavdekar A; Joglekar CV; Fall CH; Mohankrishna P; Wilkin TJ; Metcalf BS; Weedon MN; Frayling TM; Hattersley AT
    BMC Med Genet; 2006 Oct; 7():76. PubMed ID: 17032446
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.
    Habtewold A; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Burhenne J; Aklillu E
    Pharmacogenomics; 2015; 16(10):1047-64. PubMed ID: 25831219
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition.
    Shen H; Christopher L; Lai Y; Gong J; Kandoussi H; Garonzik S; Perera V; Garimella T; Humphreys WG
    Drug Metab Dispos; 2018 Aug; 46(8):1075-1082. PubMed ID: 29777022
    [TBL] [Abstract][Full Text] [Related]  

  • 99. The effect of
    Wang Y; Tian Y; Lv P; Chen L; Luo W; Jing X; Li H; Tan Z; Wang Y; Zhou H; Ouyang DS
    Pharmazie; 2017 Jun; 72(6):365-368. PubMed ID: 29442027
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions.
    Wu HF; Hristeva N; Chang J; Liang X; Li R; Frassetto L; Benet LZ
    J Pharm Sci; 2017 Sep; 106(9):2751-2757. PubMed ID: 28385543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.